Cosmos Health

Cosmos Health is a global healthcare group focused on the development and distribution of generic pharmaceuticals, nutraceuticals, and innovative repurposed drugs. The company leverages its proprietary Cloudpharm AI platform to identify and advance novel therapeutic candidates, primarily focusing on high-growth areas such as metabolic disorders and obesity. Its lead development program, CCRP-501, is an oral small molecule candidate targeting weight management through established metabolic pathways. With vertically integrated operations spanning R&D, manufacturing, and international distribution, Cosmos Health serves a wide range of patients across Europe and North America. Publicly traded on the Nasdaq, the company continues to expand its portfolio through both internal development and strategic acquisitions.